We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 1.63% | 50.03 | 49.23 | 50.80 | 50.37 | 48.85 | 49.17 | 1,363,472 | 01:00:00 |
PARIS, July 29, 2016 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN)
Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7788752-sanofi-earnings-results-q2-2016/
Q2 2016 |
Change |
Change (CER) | |
Aggregate Company sales(1) |
€8,868m |
-4.3% |
-0.2% |
Business net income(2) |
€1,680m |
-8.7% |
-3.3% |
Business EPS(3) |
€1.31 |
-7.1% |
-2.1% |
(1) Including Merial (see Appendix 10 for definition of Aggregate Company sales) which is reported on a single line in the consolidated income statements in accordance with IFRS 5 (Non-current assets held for sale and discontinued operations). Additionally, Sanofi comments include Merial for every income statement line using the term "Aggregate"; (2) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (see Appendix 10 for definitions). The consolidated income statement for Q2 2016 and H1 2016 is provided in Appendix 4 and a reconciliation of business net income to IFRS net income reported is set forth in Appendix 3; (3) (EPS) Earnings Per Share. |
Sanofi Chief Executive Officer, Olivier Brandicourt, commented:
"Our second quarter financial performance was in-line with expectations despite anticipated headwinds. Sanofi Genzyme grew 20% and, although Dengvaxia® uptake has been delayed, Sanofi Pasteur performed well. Recent highlights included the signing of the CHC asset swap, the approval of Praluent® in several countries and positive Phase III CHRONOS data for dupilumab. Following our first half performance, we confirm our broadly stable 2016 Business EPS guidance at CER."
Second quarter financial results and 2016 guidance confirmed
Performance of Global Business Units (GBU) led by Sanofi Genzyme
Major launches update
Key R&D milestones achieved
R&D update
Regulatory update
Regulatory updates since the publication of the first quarter results on April 29, 2016 include the following:
At the end of July 2016, the R&D pipeline contained 44 pharmaceutical new molecular entities (excluding Life Cycle Management) and vaccine candidates in clinical development of which 14 are in Phase III or have been submitted to the regulatory authorities for approval.
Portfolio update
Phase III:
Phase II:
Phase I:
To access the full press release of the 2016 Q2 results, please click here.
2016 guidance
Sanofi continues to expect 2016 Business EPS to be broadly stable at CER, barring unforeseen major adverse events. In addition, the currency impact on 2016 full-year business EPS is estimated to be around -4%, applying June 2016 average rates to the two remaining quarters of 2016.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Media Relations: |
Investor Relations |
Anna Robinson |
George Grofik |
908-989-0726 |
908-981-5560 |
Email: USMediaRelations@sanofi.com |
Email: IR@sanofi.com |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sanofi-announces-q2-2016-results-300306192.html
SOURCE Sanofi
Copyright 2016 PR Newswire
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions